Search research articles
Contact Us
Filters
Showing results (71-80 of 125) with videos related to
Page
of 13
Sort By:
Cancer Immunology Research
|
July 29, 2015
Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report
Isabella C Glitza, Cara Haymaker, Chantale Bernatchez, et al.
JCO Oncology Practice
|
June 23, 2026
Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy
Megan Othus, Thach-Giao Truong, Elad Sharon, et al.
Biorxiv : the Preprint Server for Biology
|
September 5, 2025
Decitabine reverses innate immune gene suppression in rare melanomas
Morgan L MacBeth, Stacey M Bagby, Jessica S W Borgers, et al.
Journal of Immunotherapy and Precision Oncology
|
November 11, 2024
A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma
Mohamed A Gouda, Bettzy Stephen, Yanyan Tian, et al.
Cancer
|
November 1, 2021
Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit
Anisha B Patel, Sahira Farooq, Macartney Welborn, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
April 23, 2013
Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination
Luis M Vence, Chiyu Wang, Himabindu Pappu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 5, 2020
Circulating Tumor Cells and Early Relapse in Node-positive Melanoma
Anthony Lucci, Carolyn S Hall, Sapna P Patel, et al.
Oncoimmunology
|
August 15, 2025
Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma
Merve Hasanov, Simin Kiany, Marie-Andrée Forget, et al.
The Oncologist
|
March 23, 2023
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience
Mirella Nardo, Bulent Yilmaz, Blessie Elizabeth Nelson, et al.
Journal for Immunotherapy of Cancer
|
September 24, 2016
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
Elizabeth I Buchbinder, Anasuya Gunturi, Jessica Perritt, et al.
Page
of 13
Search research articles
Search
Showing results (71-80 of 125) with videos related to
Sort By:
Page
of 13
Cancer Immunology Research
|
July 29, 2015
Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report
Isabella C Glitza, Cara Haymaker, Chantale Bernatchez, et al.
JCO Oncology Practice
|
June 23, 2026
Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy
Megan Othus, Thach-Giao Truong, Elad Sharon, et al.
Biorxiv : the Preprint Server for Biology
|
September 5, 2025
Decitabine reverses innate immune gene suppression in rare melanomas
Morgan L MacBeth, Stacey M Bagby, Jessica S W Borgers, et al.
Journal of Immunotherapy and Precision Oncology
|
November 11, 2024
A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma
Mohamed A Gouda, Bettzy Stephen, Yanyan Tian, et al.
Cancer
|
November 1, 2021
Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit
Anisha B Patel, Sahira Farooq, Macartney Welborn, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
April 23, 2013
Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination
Luis M Vence, Chiyu Wang, Himabindu Pappu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 5, 2020
Circulating Tumor Cells and Early Relapse in Node-positive Melanoma
Anthony Lucci, Carolyn S Hall, Sapna P Patel, et al.
Oncoimmunology
|
August 15, 2025
Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma
Merve Hasanov, Simin Kiany, Marie-Andrée Forget, et al.
The Oncologist
|
March 23, 2023
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience
Mirella Nardo, Bulent Yilmaz, Blessie Elizabeth Nelson, et al.
Journal for Immunotherapy of Cancer
|
September 24, 2016
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
Elizabeth I Buchbinder, Anasuya Gunturi, Jessica Perritt, et al.
Page
of 13